Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Nonsquamous NSCLC Harboring EGFR Mutations. Zhao B, Xing H, Ma W. J Thorac Oncol 2022;17:e76-e77.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhao B, Xing H, Ma W. Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Nonsquamous NSCLC Harboring EGFR Mutations. J Thorac Oncol 2022;17:e76-e77.
PMID: 36031292